[Cereblon as a primary target of IMiDs].

Adaptor Proteins, Signal Transducing Heterocyclic Compounds, 4 or More Rings / pharmacology Humans Immunomodulation Lupus Erythematosus, Systemic / drug therapy Lymphoma, Large B-Cell, Diffuse / drug therapy Morpholines Peptide Hydrolases / pharmacology Phthalimides Piperidones Protease Inhibitors Substrate Specificity Ubiquitin-Protein Ligases / antagonists & inhibitors
Cereblon IMiDs PROTACs Thalidomide

Journal

[Rinsho ketsueki] The Japanese journal of clinical hematology
ISSN: 0485-1439
Titre abrégé: Rinsho Ketsueki
Pays: Japan
ID NLM: 2984782R

Informations de publication

Date de publication:
2019
Historique:
entrez: 11 10 2019
pubmed: 11 10 2019
medline: 28 10 2019
Statut: ppublish

Résumé

Various derivatives of thalidomide, a drug that is well-known for its teratogenicity, have recently been developed; among them, lenalidomide and pomalidomide, known as immunomodulatory drugs (IMiDs), have potent anticancer activity. These drugs have been approved by Food and Drug Administration for the treatment of several diseases, including multiple myeloma, under strict control. The primary direct target protein of thalidomide and IMiDs is cereblon (CRBN), a substrate receptor of Cullin-RING ligase 4 (CRL4). CRL4

Identifiants

DOI: 10.11406/rinketsu.60.1013 PMID: 31597822
pubmed: 31597822
doi: 10.11406/rinketsu.60.1013
doi:

Substances chimiques

Adaptor Proteins, Signal Transducing 0
CRBN protein, human 0
Heterocyclic Compounds, 4 or More Rings 0
Morpholines 0
Phthalimides 0
Piperidones 0
Protease Inhibitors 0
iberdomide 8V66F27X44
Ubiquitin-Protein Ligases EC 2.3.2.27
Peptide Hydrolases EC 3.4.-

Types de publication

Journal Article Review

Langues

jpn

Sous-ensembles de citation

IM

Pagination

1013-1019

Auteurs

Takumi Ito (T)

Department of Nanoparticle Translational Research, Tokyo Medical University.
PRESTO, JST.

Hiroshi Handa (H)

Department of Nanoparticle Translational Research, Tokyo Medical University.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female

Evaluation of Low-Value Services Across Major Medicare Advantage Insurers and Traditional Medicare.

Ciara Duggan, Adam L Beckman, Ishani Ganguli et al.
1.00
Humans United States Aged Cross-Sectional Studies Medicare Part C

Effectiveness of Virtual Yoga for Chronic Low Back Pain: A Randomized Clinical Trial.

Hallie Tankha, Devyn Gaskins, Amanda Shallcross et al.
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH

questionsmedicales.fr › Acides aminés, peptides et protéines › Protéines › Protéines et peptides de signalisation intracellulaire › Protéines adaptatrices de la transduction du signal › [Cereblon as a primary target of IMiDs].
questionsmedicales.fr › Composés hétérocycliques › Composés hétérocycliques à cycles fusionnés › Composés hétérocycliques avec 4 noyaux ou plus › [Cereblon as a primary target of IMiDs].
questionsmedicales.fr › Eucaryotes › Animaux › Chordés › Vertébrés › Mammifères › Eutheria › Primates › Haplorhini › Catarrhini › Hominidae › Humains › [Cereblon as a primary target of IMiDs].
questionsmedicales.fr › Phénomènes du système immunitaire › Immunomodulation › [Cereblon as a primary target of IMiDs].
questionsmedicales.fr › Maladies du système immunitaire › Maladies auto-immunes › Lupus érythémateux disséminé › [Cereblon as a primary target of IMiDs].
questionsmedicales.fr › Maladies du système immunitaire › Syndromes immunoprolifératifs › Syndromes lymphoprolifératifs › Lymphomes › Lymphome malin non hodgkinien › Lymphome B › Lymphome B diffus à grandes cellules › [Cereblon as a primary target of IMiDs].
questionsmedicales.fr › Composés hétérocycliques › Composés hétéromonocycliques › Oxazines › Morpholines › [Cereblon as a primary target of IMiDs].
questionsmedicales.fr › Enzymes et coenzymes › Enzymes › Hydrolases › Peptide hydrolases › [Cereblon as a primary target of IMiDs].
questionsmedicales.fr › Composés hétérocycliques › Composés hétérocycliques à cycles fusionnés › Composés hétérobicycliques › Isoindoles › Phtalimides › [Cereblon as a primary target of IMiDs].
questionsmedicales.fr › Composés hétérocycliques › Composés hétéromonocycliques › Pipéridines › Pipéridones › [Cereblon as a primary target of IMiDs].
questionsmedicales.fr › Actions chimiques et utilisations › Actions pharmacologiques › Mécanismes moléculaires de l'action pharmacologique › Antienzymes › Inhibiteurs de protéases › [Cereblon as a primary target of IMiDs].
questionsmedicales.fr › Phénomènes chimiques › Phénomènes biochimiques › Spécificité du substrat › [Cereblon as a primary target of IMiDs].
questionsmedicales.fr › Enzymes et coenzymes › Enzymes › Ligases › Ubiquitin-protein ligase complexes › Ubiquitin-protein ligases › [Cereblon as a primary target of IMiDs].